KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2025)

Historic Convertible Debt for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Q4 2025 value amounting to $1.0 billion.

  • Alnylam Pharmaceuticals' Convertible Debt fell 164.32% to $1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year decrease of 164.32%. This contributed to the annual value of $1.0 billion for FY2025, which is 164.32% down from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Convertible Debt stood at $1.0 billion, which was down 164.32% from $1.0 billion recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Convertible Debt peaked at $1.0 billion during Q3 2025, and registered a low of $1.0 billion during Q4 2025.
  • Over the past 4 years, Alnylam Pharmaceuticals' median Convertible Debt value was $1.0 billion (recorded in 2023), while the average stood at $1.0 billion.
  • Over the last 5 years, Alnylam Pharmaceuticals' Convertible Debt had its largest YoY gain of 162.38% in 2025, and its largest YoY loss of 164.32% in 2025.
  • Quarter analysis of 4 years shows Alnylam Pharmaceuticals' Convertible Debt stood at $1.0 billion in 2022, then increased by 0.38% to $1.0 billion in 2023, then increased by 0.38% to $1.0 billion in 2024, then dropped by 1.64% to $1.0 billion in 2025.
  • Its Convertible Debt was $1.0 billion in Q4 2025, compared to $1.0 billion in Q3 2025 and $1.0 billion in Q2 2025.